mariaamparo enriquez

Reumatóloga. Ecografía MSK. Maestría en Didáctica en Ciencias de la Salud. 👩🏼‍⚕️👩🏼‍💻

[Ethic @Ethic_]

La #amistad, insólito acontecimiento en el que dos personas se sostienen en la adversidad, se conocen bien, se procuran la dicha y el cuidado; prestas a la celebración y lentas a la ira, se escuchan, se hacen mejores la una a la otra. 
https://t.co/Icfssi2ACR

[Carlos Guillén @Carlosguillenas]

La tenosinovitis estenosante de los flexores, "dedo en resorte" o "dedo en gatillo".
Infiltración entre polea y tenosinovial. Se puede hacer de otros modos, pero este es el mejor, con diferencia.
@ReumatologiaRyC

[Gabriel Puche, MD/PhD @gabi_puchepalao]

🦴 TRATAMIENTO DE LA OSTEOPOROSIS EN 2026

Si solo recuerdas una cosa para tu práctica clínica, que sea esta:

👉 El tratamiento NO depende del T-score.
👉 Depende del RIESGO DE FRACTURA.

Abro hilo 🧵👇

[mariaamparo enriquez @ferrmina]

@JaliscoVial

[Jose Ramos Vivas @joseramosvivas]

🧠🦠 Los microbios intestinales dictan nuestra agilidad mental al envejecer. 🧵👇

1️⃣ Al envejecer, aumenta la bacteria Parabacteroides goldsteinii 📈. Esta bacteria libera ácidos grasos que activan células inmunes, provocando inflamación.
2️⃣ Esta señal viaja por el nervio vago ⚡ hasta el hipocampo (el centro de la memoria), reduciendo la activación neuronal. ¡Literalmente frena tu capacidad de recordar! 🚫💾
3️⃣Al realizar trasplantes fecales de ratones jóvenes a viejos, ¡se restauró parte de la función cognitiva! 🔄✨ La microbiota es una pieza clave contra la demencia.
Cuidar tu salud intestinal no es solo digestión, es proteger tu memoria. 🍏🧘‍♂️
#Microbiota #Neurociencia #EnvejecimientoSaludable #SaludMental #Ciencia #Hippocampus #Biomedicina #NatureResearch
👇
ttps://www.nature.com/articles/d41586-026-00492-1

[Behnood Bikdeli @bbikdeli]

#Antiphospholipid antibodies and #cardiovascular #thrombosis, now in @NatRevCardiol 👇:

https://t.co/JuVuLs3s16

Systematic summary across various conditions. In some cases, we challenge the old conventional thinking...

Truly multidisciplinary, led by our 🌟fellow @SinaRsh

[JAMA @JAMA_current]

#Obesity is associated with higher risk for 12 #cancer types and accounts for approximately 10% of annual new cancer cases in the US.

📄 This Review summarizes the primary biological pathways connecting obesity and cancer development. https://t.co/L6mWf5nPUQ

[Jose Ramos Vivas @joseramosvivas]

🚨 Fantánstico Review en JAMA (publicado HOY) que destapa cómo la obesidad impulsa el cáncer a nivel molecular. 🎗️⚖️
El exceso de peso no es solo "grasa extra": el tejido adiposo se vuelve inflamatorio y hormonalmente "loco", alimentando tumores. 🧬🔥
📊 Datos crudos:
Representa el ~10% de TODOS los nuevos cánceres diagnosticados cada año en EE.UU. Hasta 50% en tipos como endometrial, hígado, páncreas, etc. 📉
🔍 Mecanismos clave que revelan que la Inflamación crónica → aumenta citoquinas (IL-6, etc.) que promueven crecimiento tumoral.
Alteraciones hormonales → estrógenos elevados y leptina que estimulan proliferación.
🦠Microbiota alterada → pérdida de bacterias protectoras como Akkermansia muciniphila. @SEMicrobiologia
Supresión del sistema inmunitario → menos T cells y NK cells que eliminan células cancerosas.🏹

💊 La Cirugía bariátrica y agonistas GLP-1 (como Ozempic/Wegovy) reducen el riesgo al bajar de peso. Pero para impacto real: >10% de pérdida de peso es el umbral clave. 🏃‍♂️🥗💉
(No he visto menciones a grants, equity, patentes o consultorías directas de fabricantes de agonistas GLP-1 o fármacos para obesidad en la revisión).
La obesidad es prevenible (en la gran mayoría de casos) → ¡moverse, comer mejor y controlar el peso salva vidas! 👇
#Obesidad #Cáncer #Prevención #JAMA #Salud #Medicina #Bienestar #Ciencia #GLP1 #PérdidaDePeso
El paper aquí ⬇️ https://t.co/jKC0EPXC7w

[NatRevRheumatol @NatRevRheumatol]

New content online: What rheumatology can learn from oncology: a patient’s perspective https://t.co/w6kchhOM6M

[Rare Disease and Orphan Drugs Journal @OAE_RDODJ]

What defines remission in SLE? Prof. Andrea Doria et al. examine remission and low disease activity as key treatment targets and their role in long-term outcomes.

🔗https://t.co/dQdrPyZkWX

#SLE #AutoimmuneDiseases #TreatToTarget #ClinicalResearch

[Alberto Giraldo @alb_giraldo]

#Procalcitonin (PCT) may be a potential inflammatory marker in the course of Still’s disease (SD), as demonstrated by a retrospective study that included 110 patients with SD and absence of infection:

◦ PCT levels were significantly higher than in healthy controls and nearly as high in macrophage activation syndrome (MAS) cases as in confirmed infections.

◦ 32% had baseline PCT ≥0.5 ng/ml; 43% had peak PCT ≥0.5 ng/ml.

◦ Elevated PCT (≥0.5) was strongly linked to:
- Higher frequency of MAS
- Higher mPouchot scores
- Greater use of biologics (especially anakinra)
- Laboratory signs of severe inflammation (thrombocytopenia, ↑ AST/LDH/CRP/ferritin, ↓ albumin)

◦ MAS risk was independently increased:
- ~4.3-fold (baseline PCT ≥0.5)
- ~5.4-fold (peak PCT ≥0.5), after multivariate adjustment

◦ PCT normalized with immunosuppressive treatment.

Although PCT cannot be used to distinguish active SD from infection, these findings suggests that increased PCT levels in patients with SD are associated with a severe inflammatory response. PCT may also serve as a potential independent predictor of MAS and could be considered a convincing marker in the assessment of non-infectious inflammation.

*Bektas E, Uludogan BC, Firlatan Yazgan B, et al. Clinical significance of non-infectious procalcitonin elevation in Still's disease: a predictor of macrophage activation syndrome. Rheumatology (Oxford). 2026;65(2):keaf575.
🔗https://t.co/ENd2yobI4B

[Dr. John Cush @RheumNow]

Antimitochondrial antibodies (AMA)in systemic sclerosis? Retro study of 165 SSc pts (20% diffuse, 33% ILD, 7% PAH); 51% centromere AB+; 29% topoisomerase I+, 12% RNA polymerase III+)-- 22% AMA-positive: assoc w/ GI vascular dz(OR 13.3), gastric antral vascular ectasia (OR 8) & may be cause for GI bleeding, refractory Fe-deficiency anemia https://t.co/ciifxmOtsX

[Dr. John Cush @RheumNow]

GLP-1s are known to improved knee OA. Using a mouse OA model w/ obesity, semaglutide yielded less pain, osteophytes & had strong chondroprotective effects, fia a wt loss-independent way. Changing from glycolysis to oxidative phosphorylation resulted in cartilage restoration. https://t.co/NVGrerfZKh

[Cristina Macía @reumacia]

Hiperuricemia y artritis psoriásica, ¡me encanta este tema!

Estudio español 🇪🇸 Acceso abierto 🔑 https://t.co/ueyNCU0QSN

[Scott Isaacs @scottisaacsmd]

Must-read Review in Nature Medicine from @DanielJDrucker: a masterclass on how GLP-1 medicines moved from glucose control to reshaping obesity, CV, liver, kidney, neuro and addiction care.
https://t.co/8ydiYIxdS0

[Dr. John Cush @RheumNow]

J Rheum full read editorial on What HLA-B27 Can—and Cannot—Tell Us!. HLA-B27 also holds prognostic and theragnostic value, given its association with greater structural damage, higher inflammatory burden, and better response to tumor necrosis factor and interleukin 17 inhib. https://t.co/iFB9ZB9M2s

[Alberto Giraldo @alb_giraldo]

Anti-Ro/SS-A and anti-La/SS-B #autoantibodies occur in ~2/3 of #Sjögren’s disease (SjD) cases and are key for diagnosis. However, ~1/3 of patients are seronegative for these, often requiring minor salivary gland biopsy for confirmation.

Emerging evidence supports novel autoantibodies for diagnosing anti-Ro/SS-A-negative SjD. Many (e.g., anti-ASCA, anti-TRIM38, anti-PUF60) associate strongly with anti-Ro/SS-A positivity, limiting seronegative utility. Promising candidates include:
◦ Anti-muscarinic M3 receptor (anti-M3R), showing high sensitivity/specificity.
◦ A 12-autoantigen panel (e.g., GMNN, GRAMD1A, NUP50) with 54% sensitivity and 100% specificity in anti-Ro/SSA-negative SjD.
◦ Validated panels: 3-marker (anti-FNBP4, anti-SNRPC, anti-CCL4) detects ~30% of anti-Ro/SSA-negative cases (specificity up to 97% vs. controls/non-SjD sicca); 5-marker (adding anti-M3R, anti-KDM6B) reaches 46% sensitivity at 95% specificity.

Other markers like anti-NA14, anti-calponin-3, anti-CCL4, anti-M5, anti-TMPO, anti-OAS3 show potential, with some (e.g., anti-TONSL, anti-IL6) linked to extraglandular features like pulmonary involvement.

Recent 2024–2025 studies confirm these panels' value in identifying seronegative SjD and predicting abnormal gland pathology, potentially reducing invasive biopsies. Larger validations and integration into diagnostics continue, advancing non-invasive tools for earlier, accurate classification in seronegative cases.

*Elsaghir A, Witte T. New autoantibodies in Sjögren's disease. Curr Opin Immunol. 2026;99:102722.
🔗https://t.co/aOXnspv2wp

[Rare Disease and Orphan Drugs Journal @OAE_RDODJ]

How is SLE managed today?
Sofia Flouda @SFlouda & Dimitrios Boumpas outline current management strategies for systemic lupus erythematosus, reflecting evolving clinical practice and therapeutic approaches.

🔗https://t.co/3h3rP8fufO
#SLE #Lupus #Rheumatology #AutoimmuneDiseases

[Orlando RPN @OrlandoRPN]

Guía Internacional para la URTICARIA: definición, clasificación, diagnóstico y tratamiento

Y mi amigo, colega, co-autor de artículos, el inmunoalergólogo César Daniel Alonso-Bello es uno de los autores principales

Para que no anden dando clorfenamina y Dexametasona a lo sonso: https://t.co/ck4HAsqdSN

[Gorka Orive @gorka_orive]

Un interesante documento sobre el potencial de la vacunación contra la varicela-zóster a la hora de reducir el riesgo de sufrir demencia. Recomiendo su lectura.
https://t.co/G5DcmSguJS